iRadimed (IRMD)
(Delayed Data from NSDQ)
$50.41 USD
+1.32 (2.69%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $50.40 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
iRadimed (IRMD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$60.00 | $60.00 | $60.00 | 22.22% |
Price Target
Only one analyst offered a short-term price target of $60.00 for iRadimed. This represents an increase of 22.22% from the last closing price of $49.09.
Analyst Price Targets (1 )
Broker Rating
iRadimed currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, two are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/2/2024 | Roth Capital Partners | Jason Wittes | Strong Buy | Strong Buy |
3/15/2024 | Lake Street Capital Markets | Frank Takkinen | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 2 |
Average Target Price | $60.00 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 96 of 252 |
Current Quarter EPS Est: | 0.38 |
IRMD FAQs
iRadimed Corporation (IRMD) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 2 brokerage firms.
The average price target for iRadimed Corporation (IRMD) is $60.00. The current on short-term price targets is based on 1 reports.
The forecasts for iRadimed Corporation (IRMD) range from a low of $60 to a high of $60. The average price target represents a increase of $19.02 from the last closing price of $50.41.
The current UPSIDE for iRadimed Corporation (IRMD) is 19.02%
Only one analyst offered a short-term price target of $60.00 for iRadimed. This represents an increase of 22.22% from the last closing price of $49.09.